NASDAQ:CHEK - Check-Cap Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.00
  • Forecasted Upside: 85.19 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.62
▼ -0.08 (-4.71%)
1 month | 3 months | 12 months
Get New Check-Cap Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CHEK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CHEK

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$3.00
▲ +85.19% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Check-Cap in the last 3 months. The average price target is $3.00, with a high forecast of $4.00 and a low forecast of $2.00. The average price target represents a 85.19% upside from the last price of $1.62.

Buy

The current consensus among 2 contributing investment analysts is to buy stock in Check-Cap. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/24/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/21/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/19/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/18/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/17/2021Dawson JamesReiterated RatingBuy ➝ Neutral$2.00Low
i
Rating by J. Kolbert at Dawson James
3/16/2021HC WainwrightBoost Price TargetBuy$1.50 ➝ $4.00High
i
11/19/2020HC WainwrightLower Price TargetBuy$2.00 ➝ $1.50Medium
i
Rating by Yi Chen at HC Wainwright
5/28/2020HC WainwrightReiterated RatingBuy$2.00Medium
i
Rating by Yi Chen at HC Wainwright
4/24/2020HC WainwrightReiterated RatingBuy$13.00 ➝ $2.00Medium
i
Rating by Yi Chen at HC Wainwright
12/31/2019HC WainwrightReiterated RatingBuy$15.00Low
i
Rating by Yi Chen at HC Wainwright
12/5/2019Dawson JamesInitiated CoverageBuy$4.00Low
i
7/10/2019HC WainwrightReiterated RatingBuy$15.00Low
i
Rating by Y. Chen at HC Wainwright
2/5/2019Dougherty & CoInitiated CoverageBuy$6.00High
i
Rating by K. Bauser at Dougherty & Co
12/14/2018HC WainwrightSet Price TargetBuy$14.00High
i
Rating by Ram Selvaraju at HC Wainwright
11/6/2018HC WainwrightSet Price TargetBuy$14.00Low
i
Rating by Ram Selvaraju at HC Wainwright
10/10/2018HC WainwrightSet Price TargetBuy$14.00Low
i
Rating by Ram Selvaraju at HC Wainwright
9/5/2018HC WainwrightReiterated RatingBuy$14.00Low
i
Rating by Ram Selvaraju at HC Wainwright
8/1/2018HC WainwrightSet Price TargetBuy$14.00High
i
Rating by Ram Selvaraju at HC Wainwright
6/6/2018HC WainwrightSet Price TargetBuy$14.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
5/23/2018HC WainwrightReiterated RatingBuy ➝ Buy$14.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
3/13/2018HC WainwrightInitiated CoverageBuy$72.00High
i
Rating by Ram Selvaraju at HC Wainwright
1/11/2018HC WainwrightBoost Price TargetBuy ➝ Buy$66.00 ➝ $72.00High
i
Rating by Ram Selvaraju at HC Wainwright
11/28/2017HC WainwrightLower Price TargetBuy ➝ Buy$84.00 ➝ $66.00High
i
Rating by R. Selvaraju at HC Wainwright
9/28/2017HC WainwrightReiterated RatingBuy ➝ Buy$72.00 ➝ $84.00High
i
Rating by Ram Selvaraju at HC Wainwright
9/27/2017Maxim GroupReiterated RatingBuy$60.00High
i
8/11/2017HC WainwrightSet Price TargetBuy$72.00High
i
Rating by Ram Selvaraju at HC Wainwright
5/30/2017Maxim GroupReiterated RatingBuyLow
i
Rating by Lauren Chung at Maxim Group
3/12/2017HC WainwrightSet Price TargetBuy$72.00Low
i
Rating by Ram Selvaraju at HC Wainwright
3/11/2017Maxim GroupSet Price TargetBuy$72.00High
i
Rating by Lauren Chung at Maxim Group
1/19/2017Rodman & RenshawInitiated CoverageBuy$72.00N/A
i
1/18/2017Maxim GroupSet Price TargetBuy$72.00N/A
i
Rating by Lauren Chung at Maxim Group
10/24/2016Maxim GroupSet Price TargetBuy$72.00N/A
i
Rating by Jason Kolbert at Maxim Group
8/1/2016Maxim GroupBoost Price TargetBuy$72.00 ➝ $132.00N/A
i
Rating by Jason Kolbert at Maxim Group
(Data available from 6/16/2016 forward)
Check-Cap logo
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a disposable system attached to the patient's back via biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis and report generation. The company was founded in 2004 and is based in Isfiya, Israel.
Read More

Today's Range

Now: $1.62
$1.61
$1.71

50 Day Range

MA: $1.55
$1.26
$1.73

52 Week Range

Now: $1.62
$0.24
$4.49

Volume

1,154,116 shs

Average Volume

15,158,338 shs

Market Capitalization

$74.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Check-Cap?

The following Wall Street analysts have issued reports on Check-Cap in the last year: Dawson James, HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for CHEK.

What is the current price target for Check-Cap?

2 Wall Street analysts have set twelve-month price targets for Check-Cap in the last year. Their average twelve-month price target is $3.00, suggesting a possible upside of 85.2%. HC Wainwright has the highest price target set, predicting CHEK will reach $4.00 in the next twelve months. Dawson James has the lowest price target set, forecasting a price of $2.00 for Check-Cap in the next year.
View the latest price targets for CHEK.

What is the current consensus analyst rating for Check-Cap?

Check-Cap currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CHEK will outperform the market and that investors should add to their positions of Check-Cap.
View the latest ratings for CHEK.

What other companies compete with Check-Cap?

How do I contact Check-Cap's investor relations team?

Check-Cap's physical mailing address is 29 ABBA HUSHI AVE. P.O.BOX 1271, ISFIYA L3, 3009000. The medical research company's listed phone number is 972546706451 and its investor relations email address is [email protected] The official website for Check-Cap is www.check-cap.com.